Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, randomized, 3-way crossover study to assess the effect of colesevelam HCl (Welchol) 3750 mg on the single dose pharmacokinetics of phenytoin sodium ER 300 mg in healthy human adult subjects.

Trial Profile

An open-label, randomized, 3-way crossover study to assess the effect of colesevelam HCl (Welchol) 3750 mg on the single dose pharmacokinetics of phenytoin sodium ER 300 mg in healthy human adult subjects.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Colesevelam (Primary) ; Phenytoin
  • Indications Epilepsy; Hypercholesterolaemia; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Daiichi Sankyo Company

Most Recent Events

  • 09 Dec 2010 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India record.
  • 10 Jun 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India record.
  • 15 Mar 2010 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top